XORTX Therapeutics (XRTX) announces receipt of notification that the patent “Xanthine Oxidase Inhibitor Formulations” will be granted by the European Patent Office. The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors, XOI, for the treatment of health consequences of chronically high uric acid, gout, renal, cardiovascular and other diseases where aberrant purine metabolism has been implicated in disease progression.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRTX:
- XORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency
- Xortx Therapeutics discloses Nasdaq notification regarding minimum bid price
- XORTX Therapeutics Releases Annual Information Form for 2024
- XORTX Therapeutics Faces Financial Challenges Amidst Operational Losses
- XORTX Advances Gout Treatment Program with FDA Discussions